Get the Stockscreener App
2.20
1.35%
-0.03
Pre-market:
2.06
-0.14
-6.36%
Phio Pharmaceuticals Corp stock is traded at $2.20, with a volume of 523.79K.
It is down -1.35% in the last 24 hours and down -10.93% over the past month.
Phio Pharmaceuticals Corp is a clinical-stage biotechnology company whose proprietary INTASYL self-delivering RNAi technology platform is designed to make immune cells more effective in killing tumor cells. The Company is developing therapeutics that are designed to leverage INTASYL to precisely target specific proteins that reduce the body's ability to fight cancer, without the need for specialized formulations or drug delivery systems.
See More
Previous Close:
$2.23
Open:
$2.14
24h Volume:
523.79K
Relative Volume:
1.58
Market Cap:
$2.32M
Revenue:
-
Net Income/Loss:
$-11.66M
P/E Ratio:
-0.2166
EPS:
-10.156
Net Cash Flow:
$-11.09M
1W Performance:
-18.52%
1M Performance:
-10.93%
6M Performance:
-65.57%
1Y Performance:
-67.49%
1-Day Range:
$2.05
$2.43
1-Week Range:
$1.53
$3.00
52-Week Range:
$1.53
$10.35
Phio Pharmaceuticals Corp Stock (PHIO) Company Profile
Name
Phio Pharmaceuticals Corp
Sector
Industry
Phone
(508) 767-3861
Address
11 APEX DRIVE, SUITE 300A, MARLBOROUGH, MA
Compare PHIO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PHIO
Phio Pharmaceuticals Corp
|
2.20 | 2.32M | 0 | -11.66M | -11.09M | -8.156 |
|
VRTX
Vertex Pharmaceuticals Inc
|
408.18 | 105.12B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
714.47 | 78.51B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
629.99 | 37.67B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
243.25 | 31.37B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
114.13 | 27.36B | 3.30B | -501.07M | 1.03B | -2.1146 |
Phio Pharmaceuticals Corp Stock (PHIO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-05-20 | Initiated | H.C. Wainwright | Buy |
Phio Pharmaceuticals Corp Stock (PHIO) Latest News
Phio Pharmaceuticals Announces Registered Direct Offering Priced At-the-Market Under Nasdaq Rules - Newsfile
Phio Pharmaceuticals Announces $480K Direct Offering with Warrant Coverage to Boost Working Capital - StockTitan
Why Rumble Shares Are Trading Higher By Around 43%; Here Are 20 Stocks Moving Premarket - Benzinga
As FedEx plans to spin off freight, can it cut costs even more? - Yahoo Finance
Phio stock hits 52-week low at $2.13 amid market challenges - Investing.com
Phio Pharmaceuticals Raises $1.15M Through Strategic Direct Offering and Warrant Placement - StockTitan
Franklin Resources (BEN-N) QuotePress Release - The Globe and Mail
Phio Pharmaceuticals Announces Positive Safety Monitoring Committee (SMC) Recommendation to Continue to Third Dose Cohort in its Clinical Study of PH-762 - Newsfile
Phio Pharmaceuticals Reports Complete Tumor Clearance in Phase 1b Cancer Trial: Key Clinical Data Released - StockTitan
Fed is weighing impact of Trump's proposed tariffs, Powell signals - Yahoo Finance
It's 'critical' home builders 'ramp up production': NAR economist - Yahoo Finance
Wall Street awaits Fed rate cut, expecting cautious tone for 2025 - Yahoo Finance
Bitcoin, 'super-bullish' sentiment, Axon: Asking for a Trend - Yahoo Finance
TCW Sticks to Bond wager Despite Losses - Yahoo Finance
Tesla clinches another record high after new bullish price targets from Wall Street - Yahoo! Voices
Broadcom stock eases on post-earnings rally as Nvidia tumbles - Yahoo Finance
Inheritance & savings: Planning challenges for LGBTQ+ individuals - Yahoo Finance
2025 will be 'a renter's market.' Redfin economist explains why. - Yahoo Finance
Phio Pharmaceuticals Announces Publication in Frontiers in Immunology - Yahoo Finance
US has a 'sickcare system,' not a healthcare system: Anomaly CEO - Yahoo Finance
Phio Pharmaceuticals is a Finalist for the Technology Disruptor of the Year Award - StockTitan
D.R. Horton (DHI-N) QuotePress Release - The Globe and Mail
Phio Pharmaceuticals to Participate in the Renmark Financial Communications Virtual Non-Deal Roadshow Series - Newsfile
Phio Pharmaceuticals to Present at Renmark Financial Virtual Roadshow - StockTitan
Elite Pharmaceuticals Announces Commercial Launch of Acetaminophen and Hydrocodone Tablets - Yahoo Finance
Phio Pharmaceuticals Announces Completion of Enrollment in Second - The Kingston Whig-Standard
Phio Pharmaceuticals Announces Completion of Enrollment in Second Cohort in Phase 1b Dose-Escalating Clinical Study - Newsfile
Phio Pharmaceuticals Corp. (PHIO) Quarterly 10-Q Report - Quartzy
Phio Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update - Alberta Daily Herald Tribune
Phio Pharma Reports 100% Tumor Clearance in Phase 1b Trial, Cuts Q3 Net Loss by 46% | PHIO Stock News - StockTitan
Phio Pharmaceuticals Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
PHIO stock touches 52-week low at $2.38 amid market challenges - Investing.com
Ligand Pharmaceuticals Inc (LGND) Q3 2024 Earnings Call Highlights: Record Revenue Growth and ... - Yahoo Finance
PHIOPhio Pharmaceuticals Corp. Latest Stock News & Market Updates - StockTitan
Phio Pharmaceuticals Announces Upcoming Presentation at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) - Newsfile
IMAX Corporation (IMAX) Hit a 52 Week High, Can the Run Continue? - Yahoo Finance
Phio Pharmaceuticals Announces Upcoming Presentation at the 39th - Shoreline Beacon
Correction to Registration Link to Access Phio Pharmaceuticals' Presentation in the Renmark Financial Communications Virtual Non-Deal Roadshow Series - Newsfile
Non-melanoma Skin Cancer is Predicted to Exhibit Remarkable - GlobeNewswire
Financial Analysis: Dianthus Therapeutics (NASDAQ:DNTH) and Phio Pharmaceuticals (NASDAQ:PHIO) - Defense World
Nasdaq Financial 100 Index (IXF) QuotePress Release - The Globe and Mail
Phio Pharmaceuticals to Participate in the Renmark Financial Communications Virtual Non-deal Roadshow Series - StockTitan
Dry Age-Related Macular Degeneration Market to Reach USD 10.57 Billion by 2032 with 9.1% CAGR – SNS Insider - GlobeNewswire
Phio Pharmaceuticals presents novel cancer therapy data - Investing.com
Phio Pharmaceuticals presents novel cancer therapy data By Investing.com - Investing.com South Africa
Phio Pharmaceuticals Presenting Data on Its INSTAYL Compound PH-894 at ASGCT's 2024 Advancing Gene and Cell Therapies for Cancer Conference - Newsfile
Phio Pharmaceuticals Presenting Data on Its INSTAYL Compound PH-894 - The Kingston Whig-Standard
Tonix Pharma Enhances Drug Development with AI Partnership - Yahoo Finance
Understanding the Risks of Investing in Phio Pharmaceuticals Corp (PHIO) - Knox Daily
Phio Pharmaceuticals Announces Presentation at the 9th Annual CAR-TCR Summit in Boston, MA - MSN
Phio Announces Data Showcasing INTASYL's Role in Helping Immune Cells Target and Kill Cancer Cells - Newsfile
Phio Pharmaceuticals Corp Stock (PHIO) Financials Data
Revenue
Net Income
Cash Flow
EPS
Phio Pharmaceuticals Corp Stock (PHIO) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Bitterman Robert J | President & CEO |
Jun 06 '24 |
Buy |
0.75 |
1,000 |
750 |
19,990 |
| Bitterman Robert J | President & CEO |
Feb 26 '24 |
Buy |
0.91 |
2,500 |
2,275 |
18,990 |
0.10%
0.76%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):